Younger age at the time of first metastasis in BRAF-mutated compared to BRAF wild-type melanoma patients

Oncology Reports

Volumn 32, Issue 2, 2014, Pages 808-814

  Saint Jean, Melanie ^a,b   Quereux, Gaëlle ^a,b   Nguyen, Jean Michel ^c   Peuvrel, Lucie ^a,b   Brocard, Anabelle ^a,b   Vallee, Audrey ^a   Knol, Anne Chantal ^a,b   Khammari, Amir ^a,b   Denis, Marc G ^a   Dréno, Brigitte ^a,b  

^a HÔTEL DIEU   (France)

^b Team 12   (France)

^c CHU DE NANTES   (France)

Author keywords

BRAF mutation; Disease free survival; Melanoma; Overall survival

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN;

ADULT; AGE; ALLELE; ARTICLE; BRAF GENE; CANCER DIAGNOSIS; CANCER PROGNOSIS; CLINICAL FEATURE; CUTANEOUS MELANOMA; DISEASE FREE SURVIVAL; DNA SEQUENCE; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; MUCOUS MELANOMA; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; SKIN METASTASIS; VISCERAL METASTASIS; WILD TYPE; AGED; GENETICS; MELANOMA; METABOLISM; METASTASIS; MIDDLE AGED; ONSET AGE; PATHOLOGY; SURVIVAL;

AGE OF ONSET; AGED; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS B-RAF; SURVIVAL ANALYSIS;

EID: 84903200628     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3265     Document Type: Article

References (26)

1. Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417: 949-954, 2002. (Pubitemid 34716871)
2. Arkenau HT, Kefford R and Long GV: Targeting BRAF for patients with melanoma. Br J Cancer 104: 392-398, 2011.
3. Chapman PB, Hauschild A, Robert C, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516, 2011.
4. Hauschild A, Grob JJ, Demidov LV, et al: Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380: 358-365, 2012.
5. Long GV, Trefzer U, Davies MA, et al: Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 13: 1087-1095, 2012.
6. Flaherty KT, Infante JR, Daud A, et al: Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367: 1694-1703, 2012.
7. Lee JH, Choi JW and Kim YS: Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol 164: 776-784, 2011.
8. Bauer J, Buttner P, Murali R, et al: BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site. Pigment Cell Melanoma Res 24: 345-351, 2011.
9. Schlaak M, Bajah A, Podewski T, et al: Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients. Br J Dermatol 168: 708-716, 2013.
10. Long GV, Menzies AM, Nagrial AM, et al: Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 29: 1239-1246, 2011.
11. Viros A, Fridlyand J, Bauer J, Lasithiotakis K, Garbe C, Pinkel D and Bastian BC: Improving melanoma classification by integrating genetic and morphologic features. PLoS Med 5: e120, 2008.
12. Houben R, Becker JC, Kappel A, Terheyden P, Brocker EB, Goetz R and Rapp UR: Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J Carcinog 3: 6, 2004.
13. Ellerhorst JA, Greene VR, Ekmekcioglu S, et al: Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res 17: 229-235, 2011.
14. Safaee Ardekani G, Jafarnejad SM, Tan L, Saeedi A and Li G: The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PLoS One 7: e47054, 2012.
15. Nagore E, Requena C, Traves V, Guillen C, Hayward NK, Whiteman DC and Hacker E: Prognostic value of BRAF mutations in localized cutaneous melanoma. J Am Acad Dermatol: Jan 2, 2014. (Epub ahead of print). doi: 10.1016/j.jaad.2013. 10.064.
16. Balch CM, Gershenwald JE, Soong SJ, et al: Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27: 6199-6206, 2009.
17. Saint-Jean M, Quereux G, Nguyen JM, et al: Is a single BRAF wild-type test sufficient to exclude melanoma patients from vemurafenib therapy? J Invest Dermatol 134: 1468-1470, 2014.
18. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247, 2009.
19. Jarry A, Masson D, Cassagnau E, Parois S, Laboisse C and Denis MG: Real-time allele-specific amplification for sensitive detection of the BRAF mutation V600E. Mol Cell Probes 18: 349-352, 2004. (Pubitemid 39061042)
20. Menzies AM, Haydu LE, Visintin L, et al: Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res 18: 3242-3249, 2012.
21. Shinozaki M, Fujimoto A, Morton DL and Hoon DS: Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin Cancer Res 10: 1753-1757, 2004. (Pubitemid 38435567)
22. V600 mutations in melanoma patients after resection of metastatic lymph nodes. Ann Surg Oncol 19: 4314-4321, 2012.
23. Colombino M, Capone M, Lissia A, et al: BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol 30: 2522-2529, 2012.
24. Lin J, Goto Y, Murata H, Sakaizawa K, Uchiyama A, Saida T and Takata M: Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression. Br J Cancer 104: 464-468, 2011.
25. Wilmott JS, Tembe V, Howle JR, et al: Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine. Mol Cancer Ther 11: 2704-2708, 2012.
26. V600E mutations in primary and metastatic melanoma. PLoS One 7: e29336, 2012.